Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Pulmonology
•
Diffuse Parenchymal Lung Disease
What factors do you consider when determining whether to perform a biopsy for the diagnosis of organizing pneumonia?
Related Questions
What dose and duration of steroid therapy do you employ while starting mycophenolate in an outpatient with relatively stable CTD-ILD?
How do you approach the use of benzodiazepines in patients with chronic medical illnesses that may be susceptible to respiratory compromise (e.g., CHF, COPD, ILD)?
What criteria do you use to determine when to start a steroid-sparing agent for hypersensitivity pneumonitis?
Would you initiate antifibrotic therapy in a patient with CTD-ILD experiencing worsening symptoms and declining lung function, despite no clear evidence of fibrosis on CT scans?
Do you ever consider tapering off steroid-sparing agents in patients with stable non-IPF ILD?
How often do you monitor pulmonary function tests in patients with fibrotic lung disease?
Have you adopted the use of low dose morphine for treatment of cough in patients with IPF?
Is there a role for nintedanib in the management of patients with radiation-induced pulmonary fibrosis?
What is your approach to treatment in a patient with radiographic UIP but pathologic evidence of both fibrotic NSIP and UIP?
How long after initiating mycophenolate do you wait before tapering prednisone off in patients with myositis-associated ILD?
